CL2022003534A1 - Combinación de alcaftadina y un corticoesteroide - Google Patents
Combinación de alcaftadina y un corticoesteroideInfo
- Publication number
- CL2022003534A1 CL2022003534A1 CL2022003534A CL2022003534A CL2022003534A1 CL 2022003534 A1 CL2022003534 A1 CL 2022003534A1 CL 2022003534 A CL2022003534 A CL 2022003534A CL 2022003534 A CL2022003534 A CL 2022003534A CL 2022003534 A1 CL2022003534 A1 CL 2022003534A1
- Authority
- CL
- Chile
- Prior art keywords
- alcaftadine
- corticosteroid
- pharmaceutically acceptable
- acceptable salt
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921053286 | 2020-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003534A1 true CL2022003534A1 (es) | 2023-06-23 |
Family
ID=76523259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003534A CL2022003534A1 (es) | 2020-06-15 | 2022-12-12 | Combinación de alcaftadina y un corticoesteroide |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| CN115485027A (zh) | 2020-03-24 | 2022-12-16 | 思瑞诺医疗有限公司 | 冠状病毒感染引起的化学感觉功能障碍的治疗 |
| US20240173331A1 (en) * | 2021-04-01 | 2024-05-30 | Alkem Laboratories Limited | Nasal compositions comprising alcaftadine |
| AU2023204805A1 (en) * | 2022-01-06 | 2024-07-25 | Cyrano Therapeutics, Inc. | Improved nasal administration of pharmaceutical formulations |
| WO2024228988A2 (en) * | 2023-05-02 | 2024-11-07 | Cyrano Therapeutics, Inc. | Treatment for taste and smell loss |
| GR1010821B (el) * | 2023-11-09 | 2024-11-15 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE84968T1 (de) | 1987-11-13 | 1993-02-15 | Asta Medica Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| IL101850A (en) * | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them |
| DE19947234A1 (de) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| ATE317268T1 (de) | 2001-12-05 | 2006-02-15 | Alcon Inc | Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis |
| PT1919450E (pt) | 2005-09-01 | 2014-09-10 | Meda Ab | Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados |
| SG170044A1 (en) * | 2006-03-31 | 2011-04-29 | Vistakon Pharmaceuticals Llc | Ocular allergy treatments |
| US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
| CN102283849A (zh) | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | 一种含有阿卡他定的药物组合物 |
| RU2652352C2 (ru) * | 2012-12-17 | 2018-04-25 | Глаксо Груп Лимитед | Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний |
| UA116793C2 (uk) * | 2013-09-13 | 2018-05-10 | Гленмарк Спешіалті С.А. | Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин |
| JP7191022B2 (ja) | 2017-07-28 | 2022-12-16 | 参天製薬株式会社 | アルカフタジン又はその塩を含有する水性医薬組成物 |
-
2021
- 2021-06-14 AU AU2021291684A patent/AU2021291684A1/en active Pending
- 2021-06-14 CA CA3181959A patent/CA3181959A1/en active Pending
- 2021-06-14 CN CN202180040805.7A patent/CN115701988A/zh active Pending
- 2021-06-14 WO PCT/IB2021/055222 patent/WO2021255622A1/en not_active Ceased
- 2021-06-14 US US17/997,656 patent/US20230218630A1/en active Pending
- 2021-06-14 KR KR1020227046470A patent/KR20230024928A/ko active Pending
- 2021-06-14 JP JP2022577618A patent/JP7791119B2/ja active Active
- 2021-06-14 MX MX2022015965A patent/MX2022015965A/es unknown
- 2021-06-14 BR BR112022024840A patent/BR112022024840A2/pt unknown
- 2021-06-14 EP EP21733564.5A patent/EP4164614A1/en active Pending
-
2022
- 2022-11-07 ZA ZA2022/12128A patent/ZA202212128B/en unknown
- 2022-12-12 CL CL2022003534A patent/CL2022003534A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230024928A (ko) | 2023-02-21 |
| CN115701988A (zh) | 2023-02-14 |
| MX2022015965A (es) | 2023-03-14 |
| EP4164614A1 (en) | 2023-04-19 |
| WO2021255622A1 (en) | 2021-12-23 |
| ZA202212128B (en) | 2024-04-24 |
| US20230218630A1 (en) | 2023-07-13 |
| JP2023530166A (ja) | 2023-07-13 |
| JP7791119B2 (ja) | 2025-12-23 |
| CA3181959A1 (en) | 2021-12-23 |
| BR112022024840A2 (pt) | 2022-12-27 |
| AU2021291684A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015965A (es) | Combinacion de alcaftadina y un corticoesteroide. | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CR20160327A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CL2023002871A1 (es) | Composiciones nasales que comprenden alcaftadina | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| CL2017001913A1 (es) | Composición tópica curativa | |
| MX2019001577A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл | |
| CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
| TR201000622A2 (tr) | Tiotropyum içeren farmasötik kombinasyonlar. | |
| BR112015025033A8 (pt) | Prodrogas de inibidores da pde-5 do tipo pirimidina bicíclica substituída | |
| MX2015003937A (es) | Composicion farmaceutica de antihistaminico no sedante e inmunosupresor antiinflamatorio. | |
| MX2021015561A (es) | Composiciones farmaceuticas que contienen dapansutrilo. | |
| BR112018068532A2 (pt) | combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas | |
| BR112015023016A2 (pt) | derivados de oxindolo carregando um substituinte oxetano e uso do mesmo para tratamento de doenças relacionadas a vasopressina |